Olet täälläEtusivu Kliininen tutkimus

Kliininen tutkimus

Measuring abuse liability-is the risk worth taking?


Early trials that supported short-term opioid treatment in the management of chronic non-cancer pain excluded patients at high risk of drug abuse, and might have overestimated the efficacy of this approach. The recent IMMPACT recommendations suggest inclusion of high-risk groups in future clinical trials of potentially addictive drugs. Is the risk worth taking?